AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16041592 — intervention group
Group type: COMPARATOR
Intervention: Conventional MRI
Number of subjects: 31
Study 12488296 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval debulking surgery (IDS)
Number of subjects: 34
Study 12488296 — intervention group
Group type: COMPARATOR
Intervention: Primary debulking surgery (PDS)
Number of subjects: 34
Study 10372468 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD assumptions (PDBQ ratings)
Number of subjects: 16
Study 10372468 — intervention group
Group type: EXPERIMENTAL
Intervention: PDBQ ratings after viewing an emotional video fragment
Number of subjects: 16
Study 10372468 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD assumptions mediating relationship with self-reported etiological factors
Number of subjects: 16
Study 8906005 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine infusion
Number of subjects: 51
Study 8906005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 1861962 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat (2.26% fluoride), n = 206, six-monthly applications
Number of subjects: 495
Study 1861962 — intervention group
Group type: COMPARATOR
Intervention: Carex (1.80% fluoride), n = 189, six-monthly applications
Number of subjects: 495
Study 6621429 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced teachers
Number of subjects: 36
Study 6621429 — intervention group
Group type: EXPERIMENTAL
Intervention: Novice teachers
Number of subjects: 36
Study 6621429 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 29846719 — intervention group
Group type: EXPERIMENTAL
Intervention: sucroferric oxyhydroxide 1.0-3.0 g/day
Number of subjects: 549
Study 29846719 — intervention group
Group type: EXPERIMENTAL
Intervention: sevelamer 2.4-14.4 g/day
Number of subjects: 549
Study 29846719 — intervention group
Group type: EXPERIMENTAL
Intervention: sucroferric oxyhydroxide or sevelamer
Number of subjects: 549
Study 28220519 — intervention group
Group type: EXPERIMENTAL
Intervention: Amustaline-treated RBCs (Test)
Number of subjects: 42
Study 28220519 — intervention group
Group type: COMPARATOR
Intervention: Control RBCs
Number of subjects: 42
Study 25667293 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Urea-based cream (UBC) plus best supportive care (BSC)
Number of subjects: 871
Study 25667293 — intervention group
Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 871
Study 22930369 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference-consistent information sharing with partners stating they understood the participants' preference.
Number of subjects: 0
Study 22930369 — intervention group
Group type: COMPARATOR
Intervention: Preference-consistent information sharing with partners stating they did not understand the participants' preference.
Number of subjects: 0
Study 19765131 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (30 ml diluted in physiologic saline) given as intravenous infusion once daily for 10 days
Number of subjects: 1060
Study 19765131 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) given as intravenous infusion once daily for 10 days
Number of subjects: 1060
Study 17515729 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Volume Tracking (BVT)
Number of subjects: 28
Study 17515729 — intervention group
Group type: COMPARATOR
Intervention: Standard Hemodialysis (SHD)
Number of subjects: 28
Study 15570253 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF
Number of subjects: 35
Study 15570253 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF plus G‐CSF
Number of subjects: 35
Study 15570253 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential administration of G‐CSF followed by GM‐CSF 6 days later
Number of subjects: 35
Study 11148742 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha blocker-finasteride combination therapy
Number of subjects: 0
Study 11148742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11148742 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study 10323611 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioengineered skin substitute (TransCyte)
Number of subjects: 21
Study 10323611 — intervention group
Group type: COMPARATOR
Intervention: Topical antibiotics (bacitracin ointment applied 2-3 times daily)
Number of subjects: 21
Study 8694728 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% apraclonidine
Number of subjects: 0
Study 8694728 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% apraclonidine
Number of subjects: 0
Study 8694728 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol
Number of subjects: 0
Study 1836087 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic treatment
Number of subjects: 0
Study 1836087 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 0
Study 6750206 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day steroids (ADS)
Number of subjects: 0
Study 6750206 — intervention group
Group type: COMPARATOR
Intervention: Daily steroids (DS)
Number of subjects: 0
Study 31430023 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fractional anisotropy in individuals at ultra-high risk for psychosis
Number of subjects: 116
Study 31430023 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower fractional anisotropy in superior longitudinal fasciculus and cingulate gyrus
Number of subjects: 116
Study 31430023 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns of cognitive functions
Number of subjects: 116
Study 31430023 — intervention group
Group type: EXPERIMENTAL
Intervention: Widespread higher fractional anisotropy
Number of subjects: 116
Study 28700420 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D video recordings
Number of subjects: 100
Study 28700420 — intervention group
Group type: COMPARATOR
Intervention: 2D video recordings
Number of subjects: 100
Study 27897989 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-low strategy (SL), CHO intake: 6 g·kg‐1·day‐1
Number of subjects: 11
Study 27897989 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON), even distribution of CHO intake
Number of subjects: 11
Study 25200049 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel
Number of subjects: 113
Study 25200049 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus placebo
Number of subjects: 113
Study 23111043 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in a simulated exsanguination and cardiac arrest emergency
Number of subjects: 171
Study 20429797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 34144
Study 20429797 — intervention group
Group type: COMPARATOR
Intervention: Conventional glucose control
Number of subjects: 34144
Study 18005932 — intervention group
Group type: EXPERIMENTAL
Intervention: One-session exposure treatment
Number of subjects: 40
Study 18005932 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-session exposure treatment
Number of subjects: 40
Study 18005932 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 40
Study 15732265 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a 44 mcg once weekly
Number of subjects: 0
Study 15732265 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a 22 mcg once weekly
Number of subjects: 0
Study 15732265 — intervention group
Group type: COMPARATOR
Intervention: Placebo/22 mcg
Number of subjects: 0
Study 15732265 — intervention group
Group type: COMPARATOR
Intervention: Placebo/44 mcg
Number of subjects: 0
Study 12958848 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil capsule (5 mg)
Number of subjects: 20
Study 12958848 — intervention group
Group type: COMPARATOR
Intervention: Donepezil tablet (5 mg)
Number of subjects: 20
Study 12958848 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil capsule
Number of subjects: 20
Study 10778658 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release formulation A (Tegretol CR, local)
Number of subjects: 12
Study 10778658 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release formulation B (Tegretol CR, Basel)
Number of subjects: 12
Study 10778658 — intervention group
Group type: COMPARATOR
Intervention: Conventional formulation (Tegretol)
Number of subjects: 12
Study 8832475 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable collagen membrane (COLL)
Number of subjects: 59
Study 8832475 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded polytetrafluoroethylene (ePTFE)
Number of subjects: 59
Study 8832475 — intervention group
Group type: COMPARATOR
Intervention: Control surgical debridement (DEBR)
Number of subjects: 59
Study 1428134 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg Vitamin K intramuscular (Menadione sodium disulphite) at birth
Number of subjects: 100
Study 1428134 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg Vitamin K intramuscular
Number of subjects: 100
Study 1428134 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg Vitamin K orally
Number of subjects: 100
Study 1428134 — intervention group
Group type: COMPARATOR
Intervention: No Vitamin K
Number of subjects: 100
Study 3883857 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized terbutaline 1 mg in 2 mL normal saline
Number of subjects: 19
Study 3883857 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous epinephrine 0.01 mg/kg (0.3 mg maximum)
Number of subjects: 19
Study 28580884 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-CBT (Motivational Interviewing integrated with Cognitive-Behavioral Therapy)
Number of subjects: 85
Study 28580884 — intervention group
Group type: COMPARATOR
Intervention: CBT alone
Number of subjects: 85
Study 30140707 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of blood glucose (BG) < 3.9 mmol/L
Number of subjects: 121
Study 30140707 — intervention group
Group type: EXPERIMENTAL
Intervention: Body surface area (BSA)
Number of subjects: 121
Study 30140707 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the curve for BG > 7.8 mmol/L
Number of subjects: 121
Study 26333683 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteochondral autograft
Number of subjects: 40
Study 26333683 — intervention group
Group type: COMPARATOR
Intervention: Osteochondral allograft
Number of subjects: 40
Study 24846622 — intervention group
Group type: COMPARATOR
Intervention: Standard implantation technique with an OVD
Number of subjects: 100
Study 24846622 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroimplantation technique
Number of subjects: 100
Study 24846622 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 100
Study 22318706 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (EPO)
Number of subjects: 138
Study 22318706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 20370945 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose in liquid (L-L)
Number of subjects: 17
Study 20370945 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid lactulose (L-S)
Number of subjects: 17
Study 20370945 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid inulin (IN-S)
Number of subjects: 17
Study 20370945 — intervention group
Group type: COMPARATOR
Intervention: Inulin (IN-S)
Number of subjects: 17
Study 20370945 — intervention group
Group type: COMPARATOR
Intervention: No substrate (NO-S)
Number of subjects: 17
Study 18568180 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 18568180 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 0
Study 15966619 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain radiography
Number of subjects: 23
Study 15966619 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital subtraction arthrography
Number of subjects: 23
Study 15966619 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide arthrography
Number of subjects: 23
Study 14583173 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemic clamp (approximately 50 mg/dl)
Number of subjects: 47
Study 14583173 — intervention group
Group type: COMPARATOR
Intervention: Euglycemic clamp (approximately 90 mg/dl)
Number of subjects: 47
Study 14583173 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise bouts at 50% VO2max
Number of subjects: 47
Study 14583173 — intervention group
Group type: COMPARATOR
Intervention: Basal leptin levels
Number of subjects: 47
Study 10572207 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 mg via Aerolizer
Number of subjects: 19
Study 10572207 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 mg via Turbuhaler
Number of subjects: 19
Study 10572207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8949363 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (30 g within 60 min)
Number of subjects: 85
Study 8501156 — intervention group
Group type: EXPERIMENTAL
Intervention: Bombesin (BBS) infusion
Number of subjects: 9
Study 8501156 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (CCK receptor antagonist)
Number of subjects: 9
Study 8501156 — intervention group
Group type: COMPARATOR
Intervention: Control saline infusion
Number of subjects: 9
Study 8501156 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide treatment alone
Number of subjects: 9
Study 3123598 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl 5 mg BID
Number of subjects: 0
Study 3123598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29604160 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan 0.75 mg/d for 6 weeks
Number of subjects: 3668
Study 27327537 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure training plus sleep health instructions
Number of subjects: 90
Study 27327537 — intervention group
Group type: COMPARATOR
Intervention: Sleep health instructions only (Control)
Number of subjects: 90
Study 26121892 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine (5 mg/kg in 2 cc/kg apple juice)
Number of subjects: 92
Study 26121892 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritonsillar infiltration of ketamine (0.5 mg/kg)
Number of subjects: 92
Study 26121892 — intervention group
Group type: COMPARATOR
Intervention: Control (2 cc/kg apple juice)
Number of subjects: 92
Study 26121892 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritonsillar infiltration of ketamine
Number of subjects: 92
Study 26121892 — intervention group
Group type: COMPARATOR
Intervention: Oral ketamine
Number of subjects: 92
Study 23691171 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 µg C-Tb
Number of subjects: 151
Study 23691171 — intervention group
Group type: COMPARATOR
Intervention: 2 TU PPD
Number of subjects: 151
Study 21683078 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 64
Study 21683078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 19366101 — intervention group
Group type: EXPERIMENTAL
Intervention: Xianling Gubao capsules
Number of subjects: 50
Study 19366101 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol and Caltrate D 600
Number of subjects: 50
Study 16630681 — intervention group
Group type: EXPERIMENTAL
Intervention: Information CD-Rom
Number of subjects: 60
Study 16630681 — intervention group
Group type: COMPARATOR
Intervention: No Information CD-Rom
Number of subjects: 60
Study 15599159 — intervention group
Group type: EXPERIMENTAL
Intervention: Arctic Sun Temperature Management System (Medivance, Louisville CO)
Number of subjects: 47
Study 15599159 — intervention group
Group type: COMPARATOR
Intervention: Conventional water‐circulating cooling blanket (Cincinnati SubZero, Cincinnati OH)
Number of subjects: 47
Study 11490105 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient factors influencing social outcome after stroke
Number of subjects: 0
Study 9935227 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin (CDDP), dacarbazine (DTIC), interferon-alpha (IFN-alpha) +/− interleukin-2 (IL-2)
Number of subjects: 7
Study 9935227 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin (CDDP), dacarbazine (DTIC), interferon-alpha (IFN-alpha) with IL-2
Number of subjects: 7
Study 9935227 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin (CDDP), dacarbazine (DTIC), interferon-alpha (IFN-alpha) without IL-2
Number of subjects: 7
Study 9935227 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 7
Study 7925516 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (10 mg quinapril plus 12.5 mg HCTZ)
Number of subjects: 368
Study 7925516 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with 10 mg quinapril
Number of subjects: 368
Study 7925516 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with 12.5 mg HCTZ
Number of subjects: 368
Study 2509737 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-type plasminogen activator at a dose of 0.05 mg/kg/hr (n = 4)
Number of subjects: 8
Study 2509737 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-type plasminogen activator at a dose of 0.025 mg/kg/hr (n = 4)
Number of subjects: 8
Study 2509737 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-type plasminogen activator (both doses)
Number of subjects: 8
Study 2509737 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary procedures
Number of subjects: 8
Study 1178359 — intervention group
Group type: EXPERIMENTAL
Intervention: binary feedback
Number of subjects: 32
Study 1178359 — intervention group
Group type: EXPERIMENTAL
Intervention: real-time, proportional feedback
Number of subjects: 32
Study 1178359 — intervention group
Group type: EXPERIMENTAL
Intervention: numerical, proportional feedback
Number of subjects: 32
Study 1178359 — intervention group
Group type: COMPARATOR
Intervention: no feedback
Number of subjects: 32
Study 28956183 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention consisting of time-skill training and compensation with time-assistive devices (TAD)
Number of subjects: 38
Study 28956183 — intervention group
Group type: COMPARATOR
Intervention: Educational intervention (Control)
Number of subjects: 38
Study 28956183 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention consisting of time-skill training and TAD
Number of subjects: 38
Study 28508180 — intervention group
Group type: EXPERIMENTAL
Intervention: Throat pack group (water-soaked throat pack gauze inserted in the mouth to occlude the oropharynx)
Number of subjects: 80
Study 28508180 — intervention group
Group type: COMPARATOR
Intervention: Non-throat pack group (no throat pack)
Number of subjects: 80
Study 28508180 — intervention group
Group type: EXPERIMENTAL
Intervention: Throat pack group
Number of subjects: 80
Study 28508180 — intervention group
Group type: COMPARATOR
Intervention: Non-throat pack group
Number of subjects: 80
Study 24983433 — intervention group
Group type: COMPARATOR
Intervention: ORIF
Number of subjects: 31
Study 24983433 — intervention group
Group type: EXPERIMENTAL
Intervention: ORIF + PSTA
Number of subjects: 31
Study 22181689 — intervention group
Group type: EXPERIMENTAL
Intervention: DOX-COL + EDTA
Number of subjects: 30
Study 22181689 — intervention group
Group type: COMPARATOR
Intervention: DOX-COL
Number of subjects: 30
Study 20835965 — intervention group
Group type: EXPERIMENTAL
Intervention: High threat information with high coping information
Number of subjects: 0
Study 20835965 — intervention group
Group type: EXPERIMENTAL
Intervention: High threat information with low coping information
Number of subjects: 0
Study 20835965 — intervention group
Group type: EXPERIMENTAL
Intervention: Low threat information with high coping information
Number of subjects: 0
Study 20835965 — intervention group
Group type: EXPERIMENTAL
Intervention: Low threat information with low coping information
Number of subjects: 0
Study 17950970 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (10-60 mg/d)
Number of subjects: 45
Study 17950970 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (25-350 mg/d)
Number of subjects: 45
Study 16029334 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol scalp solution 50 microg mL(‐1) applied twice daily for 4 days prior to chemotherapy and continued for 14 days during each treatment cycle.
Number of subjects: 24
Study 16029334 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control applied twice daily for 4 days prior to chemotherapy and continued for 14 days during each treatment cycle.
Number of subjects: 24
Study 16029334 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined results of treatment groups (calcipotriol and vehicle).
Number of subjects: 24
Study 14500162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 3.75 mg/mL
Number of subjects: 45
Study 14500162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 2 mg/mL
Number of subjects: 45
Study 14500162 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 45
Study 10656057 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g gamma‐CD (test)
Number of subjects: 24
Study 10656057 — intervention group
Group type: COMPARATOR
Intervention: 8 g maltodextrin (placebo)
Number of subjects: 24
Study 10656057 — intervention group
Group type: COMPARATOR
Intervention: Comparison of gamma‐CD and maltodextrin
Number of subjects: 24
Study 2192462 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily injections of growth hormone (0.3 mg/kg weekly)
Number of subjects: 47
Study 2192462 — intervention group
Group type: COMPARATOR
Intervention: Three times weekly injections of growth hormone (0.3 mg/kg weekly)
Number of subjects: 47
Study 2192462 — intervention group
Group type: COMPARATOR
Intervention: Once a week injections of growth hormone (0.3 mg/kg weekly)
Number of subjects: 47
Study 2192462 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily injections of growth hormone (after switching from once or three times a week)
Number of subjects: 47
Study 336453 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone sodium
Number of subjects: 44
Study 336453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 31251094 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 75 mg intravenously (MENSA)
Number of subjects: 1755
Study 31251094 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg subcutaneously (MUSCA)
Number of subjects: 1755
Study 31251094 — intervention group
Group type: COMPARATOR
Intervention: Historical exacerbations
Number of subjects: 1755
Study 31251094 — intervention group
Group type: COMPARATOR
Intervention: Within-study severe exacerbations (MENSA)
Number of subjects: 1755